JC viral reactivation in a pediatric patient with Crohn's disease

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 3, 2010, Pages 955-959

  Bellizzi, A ^a   Barucca, V ^a   Di Nardo, G ^a   Fioriti, F ^b   Iebba, V ^a   Schippa, S ^a   Conte, M P ^a   Proietti Checchi, M ^a   Colosimo, M T ^a   Cucchiara, S ^a   Oliva, S ^a   Chiarini, F ^a   Pietropaolo, Valeria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

5 ASA; Crohn's disease; JCV reactivation; PML

Indexed keywords

MESALAZINE; POLYMER; SALAZOSULFAPYRIDINE; STEROID; VIRUS DNA;

ABDOMINAL PAIN; ARTICLE; CASE REPORT; CECUM; CHILD; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DIET THERAPY; FEMALE; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE BIOPSY; JC VIRUS; PATIENT MONITORING; PRIORITY JOURNAL; RECTUM; SCHOOL CHILD; SIDE EFFECT; VIRUS DETECTION; VIRUS REACTIVATION;

EID: 78149257692     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300333     Document Type: Article

References (16)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407.
2. Bellizzi A, Barucca V, Fioriti D, Colosimo MT, Mischitelli M, Anzivino E, Chiarini F, Pietropaolo V. Early years of biological agents therapy in Crohn's disease and risk of the human Polyomavirus JC reactivation. J Cell Physiol 2010; 224:316-26.
3. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010; 45:9-16.
4. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009; 3:77-97.
5. Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, Boland CR. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 2000; 119:1228-35.
6. Selgrad M, De Giorgio R, Fini L, et al. JC Virus Infects the Enteric Glia of Patients with Chronic Idiopathic Intestinal Pseudo-obstruction. Gut 2009; 58:25-32.
7. Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans? Semin Cancer Biol 2009; 19:261-9.
8. Frisque RJ, Hofstetter C, Tyagarajan SH. Trasforming activities of JC virus early proteins. Adv Exp Med Biol 2006; 577:288-309.
9. White MK, Gordon J, Reiss K, Del Valle L, Croul S, Giordano A, Darbinyan A, Khalili K. Human polyomaviruses and brain tumors. Brain Res Rev 2005; 50:69-85.
10. Jung WT, Li MS, Goel A, Boland CR. JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer 2008; 112:1028-36.
11. Shin SK, Li MS, Fuerst F, Hotchkiss E, Meyer R, Kim IT, Goel A, Boland CR. Oncogenic T-Antigen of JC Virus is present frequently in human gastric cancers. Cancer 2006; 107:481-8.
12. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14:1169-79.
13. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-8.
14. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008; 57:1393-7.
15. Delbue S, Branchetti E, Boldorini R, Vago L, Zerbi P, Veggiani C, Tremolada S, Ferrante P. Presence and expression of JCV early gene large T Antigen in the brains of immunocopromised and immunocompetent individuals. J Med Virol 2008; 80:2147-52.
16. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.